Xenobiotic and endobiotic inhibitors of cytochrome p-450dbl function, the target of the debrisoouine/sparteine type polymorphism
- 1 October 1988
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 37 (20), 3829-3835
- https://doi.org/10.1016/0006-2952(88)90063-9
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidationXenobiotica, 1986
- Does an endogenous methylpyridinium analogue cause Parkinson's disease?Journal of Pharmacy and Pharmacology, 1985
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984
- A human cytochrome P-450 characterized by inhibition studies as the sparteine–debrisoquine monooxygenaseCanadian Journal of Physiology and Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Interaction of Chlorpromazine and Nortriptyline in Patients with SchizophreniaClinical Pharmacokinetics, 1981
- Genetic evidence for the involvement of different oxidative mechanisms in drug oxidationJournal of Pharmacy and Pharmacology, 1979